Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 65 years of age
- People who have been diagnosed with sudden unexplained hearing loss — specifically, a significant drop in hearing across three connected sound frequencies — within 14 days of their symptoms starting
- People whose hearing loss did not improve with an initial course of steroid tablets (such as prednisone), or who were unable to take steroid tablets for medical reasons
- People who are willing and able to sign a written consent form agreeing to take part
Who may not be able to join:
- People whose hearing loss has a known cause, such as a tumour on the hearing nerve, Menière's disease, or a physical injury
- People who already had severe or profound hearing loss in the affected ear before this episode
- People who currently have an active infection in the middle ear or a hole in the eardrum
- People with a history of autoimmune disease, blood clotting disorders, or a weakened immune system
- People who are pregnant or currently breastfeeding
- People who have a known allergy or sensitivity to dexamethasone (a steroid medication) or to any ingredient in the exosome treatment being studied
- People who have taken part in another interventional clinical trial within the past 30 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +201012788746
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To compare the efficacy of a single course of Intratympanic Exosomes-Dexamethasone versus conventional IT dexamethasone and exosome vehicle alone As measured by the mean change in pure-tone average (PTA; 0.5, 1, 2, 4 kHz) from baseline to the 4-week post; Exosomes Efficacy As measured by the mean change in pure-tone average (PTA; 0.5, 1, 2, 4 kHz) from baseline to the 4-week post-treatment endpoint
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.